PTPI vs MNKD

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). MannKind Corporation (MNKD) offers the better valuation at 176. 0x trailing P/E, making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, MannKind Corporation (MNKD) delivered a total return of -13.

5%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: MNKD returned -46. 7% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MannKind Corporation (MNKD) is the lower-risk stock at 1.

09β versus Petros Pharmaceuticals, Inc. 's 1. 45β — meaning PTPI is approximately 33% more volatile than MNKD relative to the S&P 500.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Petros Pharmaceuticals, Inc. grew EPS 47. 4% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MannKind Corporation (MNKD) is the more profitable company, earning 1.

7% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — MNKD leads at 82. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, PTPI (100.

0% yield) pays a dividend. MNKD does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Petros Pharmaceuticals, Inc.

(PTPI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (100. 0% yield). Both have compounded well over 10 years (PTPI: -100. 0%, MNKD: -46. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTPI is a small-cap income-oriented stock; MNKD is a small-cap high-growth stock. PTPI pays a dividend while MNKD does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.